Effect of anlotinib as a third‐ or further‐line therapy in advanced non‐small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial... by Ying Cheng, Baohui Han, Kai Li, Qiming Wang, Li Zhang, Jianhua Shi, Zhehai Wang, Jianxing He, Yuankai Shi, Weiqiang Chen, Xiuwen Wang, Yi Luo, Kejun Nan, Faguang Jin, Baolan Li, Jing Zhu

Subjects: Get full text

Panitumumab versus cetuximab in combination with irinotecan in refractory metastatic colorectal cancer by Maria Ignez Freitas Melro Braghiroli, Daniel Santos Rocha Sobral Filho, Juliana Goes Martins Fagundes, Elizabeth Zambrano Mendoza, Maria Fernanda Batistuzzo Vicentini Neffa, Karla Souza Campos, Leonardo Gomes da Fonseca, Renata Colombo Bonadio, Aley Talans, Oddone Freitas Melro Braghiroli, Maria Cecília Mathias-Machado, Jorge Sabbaga, Camila Motta Venchiarutti Moniz, Paulo Marcelo Gehm Hoff

Subjects: Get full text

Pooled safety analysis of two phase 3 studies investigating trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer by Julien Taieb, Marwan Fakih, Gabor Liposits, Gerald W. Prager, Eric Van Cutsem, Fortunato Ciardiello, Nadia Amellal, Elizabeth Calleja, Mei Liu, Lucas Roby, Josep Tabernero, Thierry André

Subjects: Get full text

HIV drug resistance, early treatment outcomes and impact of guidelines compliance after protease inhibitor‐based second‐line failure in a dedicated resistance clinic in western Ken... by John M. Humphrey, Shamim M. Ali, Allison DeLong, Vlad Novitsky, Edwin Sang, Bilal Jawed, Emmanuel Kemboi, Celia Ngetich, Suzanne Goodrich, Adrian Gardner, Joseph W. Hogan, Rami Kantor

Subjects: Get full text

Real‐World Response and Survival Outcomes and Treatment Patterns in Patients With Extensive Stage Small‐Cell Lung Cancer Receiving Third‐Line Treatment by Jair Bar, Qingqing Xu, Sudeep Karve, Pooja Hingorani, Amin A. Virani, Neal E. Ready

Subjects: Get full text

Efficacy of third-line chemotherapy following nanoliposomal irinotecan combined with fluorouracil and folinic acid as second-line treatment for unresectable pancreatic cancer by Keisuke Miwa, Reina Kawasaki, Mototsugu Shimokawa, Mototsugu Shimokawa, Taiga Otsuka, Toshimitsu Tanaka, Masaru Fukahori, Taro Shibuki, Taro Shibuki, Junichi Nakazawa, Shiho Arima, Futa Koga, Yujiro Ueda, Yoshihito Kubotsu, Hozumi Shimokawa, Hozumi Shimokawa, Shigeyuki Takeshita, Kazuo Nishikawa, Azusa Komori, Azusa Komori, Satoshi Otsu, Ayumu Hosokawa, Tatsunori Sakai, Hisanobu Oda, Machiko Kawahira, Shuji Arita, Takuya Honda, Hiroki Taguchi, Hiroki Taguchi, Kengo Tsuneyoshi, Toshihiro Fujita, Takahiro Sakae, Yasunori Kawaguchi, Tsuyoshi Shirakawa, Tsuyoshi Shirakawa, Toshihiko Mizuta, Kenji Mitsugi

Subjects: Get full text

Viral load suppression rate of third-line antiretroviral therapy and its association with gender among HIV patients after second-line treatment failure in Africa: a systematic revi... by Tilahun Degu Tsega, Sintayehu Simie Tsega, Asaye Alamneh Gebeyehu, Getaneh Atikilt Yemata, Rahel Mulatie Anteneh, Almaw Genet Yeshiwas, Getasew Yirdaw, Chalachew Yenew, Anley Shiferaw Enawgaw, Amare Genetu Ejigu, Ahmed Fentaw Ahmed, Zeamanuel Anteneh Yigzaw, Berhanu Abebaw Mekonnen, Meron Asmamaw Alemayehu, Abathun Temesgen, Abebaw Molla, Habitamu Mekonen, Assefa Andargie Kassa, Gashaw Melkie Bayeh

Subjects: “…Third line antiretroviral therapy…”
Get full text

Survival Outcomes with Regorafenib and/or Trifluridine/Tipiracil Sequencing to Rechallenge with Third-Line Regimens in Metastatic Colorectal Cancer: A Multicenter Retrospective Rea... by Carlo Signorelli, Maria Alessandra Calegari, Annunziato Anghelone, Alessandro Passardi, Giovanni Luca Frassineti, Alessandro Bittoni, Jessica Lucchetti, Lorenzo Angotti, Emanuela Di Giacomo, Ina Valeria Zurlo, Cristina Morelli, Emanuela Dell’Aquila, Adele Artemi, Donatello Gemma, Domenico Cristiano Corsi, Alessandra Emiliani, Marta Ribelli, Federica Mazzuca, Giulia Arrivi, Federica Zoratto, Mario Giovanni Chilelli, Marta Schirripa, Maria Grazia Morandi, Fiorenza Santamaria, Manuela Dettori, Antonella Cosimati, Rosa Saltarelli, Alessandro Minelli, Emanuela Lucci-Cordisco, Michele Basso

Subjects: Get full text

Estimated cost of VEGFR TKI associated adverse events in metastatic renal cell carcinoma patients by Jeffrey Thomas Yorio, Aviva G. Asnis-Alibozek, Vijay Kasturi, Thomas E. Hutson

Subjects: Get full text

Pharmacoeconomic efficacy of atesolizumab compared with other PD-1 inhibitors in patients with advanced non-small cell lung cancer after chemotherapy by S. K. Zyryanov, I. N. Diyakov

Subjects: Get full text

Updated pharmacoeconomic analysis of atesolizumab efficiency compared with other PD-1 inhibitors in patients with advanced non-small cell lung cancer after chemotherapy by S. K. Zyryanov, I. N. Dyakov

Subjects: Get full text